ClinicalTrials.gg
Enrolling by invitationNCT07169383MelasmaUpdated Sep 11, 2025

Oral Melatonin Versus Oral Tranexamic Acid in the Management of Melasma

A Phase 2 interventional study of Melatonin tablet and Tranexamic Acid (TXA) in Melasma (Facial Melasma), sponsored by Hina Malik. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Hina Malik · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing Tranexamic Acid in Melanosis — 6 open to participants now, 7 under way, 2 of them phase 3. Tranexamic Acid · Melanosis.

Planned enrollment
2nd of 16
160 · median 52
Started
2025
the only one that year
Phase 2
Only one
of the 16
Registered
12th of 16
by date
Lead sponsor
1 of 16
Hina Malik

Among the 16 studies testing Tranexamic Acid in Melanosis, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2, and was the 12th registered.

Melanosis

170 studies on the registry are indexed under Melanosis; 46 are open to participants now.

Browse Melanosis studies →

Open to participants now

6 of the 16 studies testing Tranexamic Acid in Melanosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Melanosis studies recruiting now, 8 (42%) set no upper age limit and 11 (58%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing Tranexamic Acid in Melanosis, or all of them as a file.
02

Study summary

This study will compare the efficacy of oral melatonin and oral tranexamic acid in treating melasma, with the aim of determining whether melatonin is more effective than tranexamic acid, as measured by MASI scores. Literature suggests melatonin may be more effective due to its antioxidant, anti-inflammatory, and anti-melanogenic properties. The findings will assess whether melatonin provides better efficacy and tolerance compared to tranexamic acid in managing this persistent condition. Efficacy will be assessed by comparing the baseline MASI scores with the scores obtained at six-week and twelve-week follow-up points based on the following cut-offs:

\<25% improvement Mild response 25-50% improvement Moderate Response 51-75% improvement Good response >75% improvement Excellent Response

Read the detailed description

This study will compare the efficacy of oral melatonin and oral tranexamic acid in treating melasma.Literature suggests melatonin may be more effective due to its antioxidant, anti-inflammatory, and anti-melanogenic properties.Efficacy will be assessed by comparing the baseline MASI scores with the scores obtained at six-week and twelve-week follow-up points based on the following cut-offs:

\<25% improvement Mild response 25-50% improvement Moderate Response 51-75% improvement Good response >75% improvement Excellent Response It's a Randomized Control Trial conducted at PAEC General Hospital. Study period is of 6 months.Total sample size is 180 patents.The sample is divided into two groups, with 80 patients assigned to each treatment.This study hypothesizes that oral melatonin will be more effective than oral tranexamic acid in reducing the severity of melasma, as measured by changes in the Melasma Area and Severity Index.

03

Conditions studied

  • Melasma (Facial Melasma)

Browse trials for

Keywords

  • Management of Melasma
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18-50 years diagnosed with melasma.

    • Both genders.

Exclusion criteria

  • Patients with to melatonin, including pregnancy, breastfeeding, disorders, bleeding disorders, and diabetes, or contraindications to tranexamic acid, including thromboembolic events, history of thrombosis, renal impairment, and pregnancy or breastfeeding.

    • Patients with a history of to any of the medications.
    • Patients already taking treatment of melasma
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Group A - Oral melatonin

    Group A will receive oral melatonin 5mg daily at night for 3 months after ruling out any contraindications. Melasma Area and severity index will be calculated at day one , 6 weeks and 12 weeks.

    Drug: Melatonin tablet

  • Active comparator
    Group B - Oral tranexamic acid

    Group B will receive oral tranexamic acid 250mg twice daily for 3 months after ruling out any contraindications.Melasma area and severity index will than be calculated on day one , 6 weeks and 12 weeks.

    Drug: Tranexamic Acid (TXA)

Interventions

06

What researchers measure

Primary outcomes

  1. Total participants are 160, 80 in Group A and 80 in Group B

    Group A will receive oral melatonin 5mg HS for 12 weeks and Group B will receive oral tranexamic acid 250 mg BD for 12 weeks and then the improvement will be assessed by calculating MASI score at day 1, 6weeks and 12 weeks.MASI score less than 10 is considered mild , 11-20 is considered moderate and more than 20 is considered Severe Melasma. An improvement greater than 25% in the MASI score will be considered as the threshold for treatment efficacy.

    Time frame: 12 weeks

  2. Efficacy of Oral Melatonin VS Oral Tranexamic Acid in the management of Melasma

    As per literature Melatonin may be more effective due to its Antioxidant, Anti-inflammatory and anti-melanogenic properties. The findings will assess whether Melatonin provides better efficacy and tolerance compared to Tranexamic Acid in managing Melasma.An improvement greater than 25% in the MASI score will be considered as the threshold for treatment efficacy.

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The plan to share de-identified individual participant data (IPD) from this clinical trial, including the efficacy of oral melatonin versus oral tranexamic acid in managing melasma, with researchers who submit a methodologically sound proposal for secondary analysis. The data shared will include the primary and secondary outcome measures, participant demographics, and other relevant study data. Data will be accessible 12 months after the primary publication of the trial results, via a secure online platform, with a data use agreement. Access will be granted to researchers who provide a detailed proposal and agree to the terms of data sharing, including maintaining participant confidentiality and not attempting to re-identify participants. Requests for data access should be directed to dr.hina567@gmail.com This IPD sharing plan aligns with the ICMJE's expectations for data sharing and transparency in clinical trials.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: January 2026 to janurary 2027

Access criteria: De-identified IPD will be shared with qualified researchers who submit a proposal for secondary analysis that aligns with the trial's objectives and methodology. Proposals must outline planned analyses, including statistical methods, and will be reviewed by an independent committee for scientific merit and feasibility. A data sharing agreement must be signed, ensuring participant confidentiality and data protection. Requests can be sent to dr.hina567@gmail.com. Access will be granted for analyses that advance knowledge in melasma management, such as exploring treatment efficacy, safety, or predictors of response.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Sep 11, 2025
StartActual
Jun 28, 2025
Primary completionEst.
Dec 28, 2025
CompletionEst.
Dec 28, 2025
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07169383
Lead sponsor
Hina Malik
Responsible party
Hina Malik (Post Graduate Trainee, PAEC General Hospital, Islamabad) — Sponsor-investigator
First posted
Sep 11, 2025
Start date
Jun 28, 2025
Primary completion
Dec 28, 2025 (estimated)
Completion
Dec 28, 2025 (estimated)
Last update
Sep 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Melatonin · Tranexamic Acid

Start the discussion